{"title":"双膦酸盐对缓解耳硬化症相关耳鸣的疗效:一项前瞻性病例对照研究","authors":"Ayman Fouad, Mahmoud Mandour, Mohamed Osama Tomoum, Reham Mamdouh Lasheen","doi":"10.1007/s00405-024-08935-z","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To investigate the short-term efficacy of third-generation bisphosphonate in the management of tinnitus associated with otosclerosis.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A prospective case–control study included 100 patients with otosclerosis-associated bothersome tinnitus. Patients were assigned to two groups: group A (control): 25 patients who planned to receive only complementary supplements, oral vitamin D plus calcium, and group B (case): 75 patients who planned to receive oral bisphosphonate plus routine vitamin D and calcium supplements. Group B was subdivided into B<sub>1</sub>: 25 patients without any previous intervention, B<sub>2</sub>: 25 patients with persistent tinnitus for more than 6 months after a previous uncomplicated stapedotomy in the same ear, and B<sub>3</sub>: 25 patients with persistent tinnitus for more than 6 months after hearing aid fitting. The outcome was tinnitus assessment both subjectively (tinnitus intensity, frequency, and questionnaire) and objectively (tinnitus intensity and frequency).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The female-to-male ratio was 1.6:1 with ages ranging from 40 to 61 years. The baseline revealed no statistically significant differences between the groups. After 6 months, there were statistically significant differences, both objectively and subjectively. The tinnitus questionnaire median (IQR) for group B was 16 (30), whereas control group A had 52 (24). The tinnitus severity median (IQR) for group B was 20 (30), compared to group A’s 52 (42). After 6 months, 40% of the cases in group B demonstrated complete improvement, compared to 0% in control group A.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>We demonstrated significant tinnitus improvement in cases treated with bisphosphonate compared to the control group.</p>","PeriodicalId":11952,"journal":{"name":"European Archives of Oto-Rhino-Laryngology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of bisphosphonate for alleviating tinnitus associated with otosclerosis: a prospective case–control study\",\"authors\":\"Ayman Fouad, Mahmoud Mandour, Mohamed Osama Tomoum, Reham Mamdouh Lasheen\",\"doi\":\"10.1007/s00405-024-08935-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>To investigate the short-term efficacy of third-generation bisphosphonate in the management of tinnitus associated with otosclerosis.</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>A prospective case–control study included 100 patients with otosclerosis-associated bothersome tinnitus. Patients were assigned to two groups: group A (control): 25 patients who planned to receive only complementary supplements, oral vitamin D plus calcium, and group B (case): 75 patients who planned to receive oral bisphosphonate plus routine vitamin D and calcium supplements. Group B was subdivided into B<sub>1</sub>: 25 patients without any previous intervention, B<sub>2</sub>: 25 patients with persistent tinnitus for more than 6 months after a previous uncomplicated stapedotomy in the same ear, and B<sub>3</sub>: 25 patients with persistent tinnitus for more than 6 months after hearing aid fitting. The outcome was tinnitus assessment both subjectively (tinnitus intensity, frequency, and questionnaire) and objectively (tinnitus intensity and frequency).</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>The female-to-male ratio was 1.6:1 with ages ranging from 40 to 61 years. The baseline revealed no statistically significant differences between the groups. After 6 months, there were statistically significant differences, both objectively and subjectively. The tinnitus questionnaire median (IQR) for group B was 16 (30), whereas control group A had 52 (24). The tinnitus severity median (IQR) for group B was 20 (30), compared to group A’s 52 (42). After 6 months, 40% of the cases in group B demonstrated complete improvement, compared to 0% in control group A.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>We demonstrated significant tinnitus improvement in cases treated with bisphosphonate compared to the control group.</p>\",\"PeriodicalId\":11952,\"journal\":{\"name\":\"European Archives of Oto-Rhino-Laryngology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Archives of Oto-Rhino-Laryngology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00405-024-08935-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Oto-Rhino-Laryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00405-024-08935-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的 探讨第三代双膦酸盐治疗耳硬化症相关耳鸣的短期疗效。方法 一项前瞻性病例对照研究纳入了 100 名耳硬化症相关困扰性耳鸣患者。患者被分为两组:A 组(对照组):A 组(对照组):25 名患者只计划接受补充营养品,即口服维生素 D 和钙剂;B 组(病例组):75 名患者计划接受口服维生素 D 和钙剂:75名患者计划接受口服双膦酸盐加常规维生素D和钙补充剂。B 组又分为 B1 组:25 名既往未接受过任何干预的患者;B2 组:25 名既往接受过同耳非复杂性镫骨切除术后持续耳鸣超过 6 个月的患者;B3 组:25 名验配助听器后持续耳鸣超过 6 个月的患者。结果对耳鸣进行了主观评估(耳鸣强度、频率和问卷调查)和客观评估(耳鸣强度和频率)。基线数据显示,两组之间没有明显的统计学差异。6 个月后,客观和主观方面的差异均有统计学意义。B 组的耳鸣问卷中位数(IQR)为 16(30),而对照 A 组为 52(24)。B 组耳鸣严重程度的中位数(IQR)为 20(30),而 A 组为 52(42)。6 个月后,B 组 40% 的病例完全好转,而对照组 A 为 0%。
Effectiveness of bisphosphonate for alleviating tinnitus associated with otosclerosis: a prospective case–control study
Purpose
To investigate the short-term efficacy of third-generation bisphosphonate in the management of tinnitus associated with otosclerosis.
Methods
A prospective case–control study included 100 patients with otosclerosis-associated bothersome tinnitus. Patients were assigned to two groups: group A (control): 25 patients who planned to receive only complementary supplements, oral vitamin D plus calcium, and group B (case): 75 patients who planned to receive oral bisphosphonate plus routine vitamin D and calcium supplements. Group B was subdivided into B1: 25 patients without any previous intervention, B2: 25 patients with persistent tinnitus for more than 6 months after a previous uncomplicated stapedotomy in the same ear, and B3: 25 patients with persistent tinnitus for more than 6 months after hearing aid fitting. The outcome was tinnitus assessment both subjectively (tinnitus intensity, frequency, and questionnaire) and objectively (tinnitus intensity and frequency).
Results
The female-to-male ratio was 1.6:1 with ages ranging from 40 to 61 years. The baseline revealed no statistically significant differences between the groups. After 6 months, there were statistically significant differences, both objectively and subjectively. The tinnitus questionnaire median (IQR) for group B was 16 (30), whereas control group A had 52 (24). The tinnitus severity median (IQR) for group B was 20 (30), compared to group A’s 52 (42). After 6 months, 40% of the cases in group B demonstrated complete improvement, compared to 0% in control group A.
Conclusion
We demonstrated significant tinnitus improvement in cases treated with bisphosphonate compared to the control group.
期刊介绍:
Official Journal of
European Union of Medical Specialists – ORL Section and Board
Official Journal of Confederation of European Oto-Rhino-Laryngology Head and Neck Surgery
"European Archives of Oto-Rhino-Laryngology" publishes original clinical reports and clinically relevant experimental studies, as well as short communications presenting new results of special interest. With peer review by a respected international editorial board and prompt English-language publication, the journal provides rapid dissemination of information by authors from around the world. This particular feature makes it the journal of choice for readers who want to be informed about the continuing state of the art concerning basic sciences and the diagnosis and management of diseases of the head and neck on an international level.
European Archives of Oto-Rhino-Laryngology was founded in 1864 as "Archiv für Ohrenheilkunde" by A. von Tröltsch, A. Politzer and H. Schwartze.